ALS drug trial ends early after just one participant
Disease control
Terminated
This study tested a new drug, STR04, in people with ALS, a disease that weakens muscles over time. Only one person took part before the study was stopped early. The goal was to see if the drug was safe and if it could slow down the disease, but no clear results are available due …
Phase: PHASE2 • Sponsor: New England Cell Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC